🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

342 results for “Novartis Pharmaceuticals” Clear

  1. Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, VAY736, -

    Novartis Pharmaceuticals

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  2. Placebo to remibrutinib (LOU064) 25 mg film-coated tablet, -, LOU064, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  3. QAW039

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  4. QAW039 150 mg

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  5. QMF149

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule active

    1 trial

  6. QMF149 150/80 μg

    Novartis Pharmaceuticals

    Mild Asthma

    phase 3 small molecule completed

    1 trial

  7. QVA149

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  8. QVM149 150/50/160

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  9. RAD001

    Novartis Pharmaceuticals

    Tuberous Sclerosis Complex-associated Refractory Seizures

    phase 3 small molecule completed

    1 trial

  10. ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  11. ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  12. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity

    phase 3 small molecule completed

    1 trial

  13. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    1 trial

  14. Ranibizumab 0.5 mg

    Novartis Pharmaceuticals

    Central Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  15. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  16. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria

    phase 3 small molecule active

    1 trial

  17. Ribociclib

    Novartis Pharmaceuticals

    Advanced, Metastatic Breast Cancer

    phase 3 small molecule completed

    1 trial

  18. Ribociclib

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  19. Ruxolitinib

    Novartis Pharmaceuticals

    Polycythemia Vera

    phase 3 small molecule completed

    1 trial

  20. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  21. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  22. Secukinumab

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  23. Secukinumab

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    2 trials

  24. Secukinumab

    Novartis Pharmaceuticals

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources